These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27049723)

  • 1. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
    Deng J; Park D; Wang M; Nooka A; Deng Q; Matulis S; Kaufman J; Lonial S; Boise LH; Galipeau J; Deng X
    Oncotarget; 2016 May; 7(19):27753-63. PubMed ID: 27049723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
    Han B; Park D; Li R; Xie M; Owonikoko TK; Zhang G; Sica GL; Ding C; Zhou J; Magis AT; Chen ZG; Shin DM; Ramalingam SS; Khuri FR; Curran WJ; Deng X
    Cancer Cell; 2015 Jun; 27(6):852-63. PubMed ID: 26004684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
    Vervloessem T; Sasi BK; Xerxa E; Karamanou S; Kale J; La Rovere RM; Chakraborty S; Sneyers F; Vogler M; Economou A; Laurenti L; Andrews DW; Efremov DG; Bultynck G
    Cell Death Dis; 2020 Sep; 11(9):769. PubMed ID: 32943617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
    Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
    Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth.
    Lin Y; Zhao Y; Chen M; Li Z; Liu Q; Chen J; Ding Y; Ding C; Ding Y; Qi C; Zheng L; Li J; Zhang R; Zhou J; Wang L; Zhang QQ
    BMC Cancer; 2023 May; 23(1):479. PubMed ID: 37237269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular dynamics investigations of structural and functional changes in Bcl-2 induced by the novel antagonist BDA-366.
    Li T; Cui Y; Wu B
    J Biomol Struct Dyn; 2019 Jul; 37(10):2527-2537. PubMed ID: 30047840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BH4 domain of Bcl-2 as a novel target for cancer therapy.
    Liu Z; Wild C; Ding Y; Ye N; Chen H; Wold EA; Zhou J
    Drug Discov Today; 2016 Jun; 21(6):989-96. PubMed ID: 26631752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
    Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Inhibition of BCL2 Shows Antitumor Effects in Lung Cancer.
    Cancer Discov; 2015 Jul; 5(7):OF21. PubMed ID: 26045015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
    Turner BC; Eves T; Refaeli Y
    DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Implications of the spectrum of BCL2 mutations in Lymphoma.
    Singh K; Briggs JM
    Mutat Res Rev Mutat Res; 2016; 769():1-18. PubMed ID: 27543313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
    Lin J; Wu Y; Yang D; Zhao Y
    Oncol Rep; 2013 Aug; 30(2):731-8. PubMed ID: 23708869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonizing Bcl-2's BH4 domain in cancer.
    Vervloessem T; La Rovere R; Bultynck G
    Aging (Albany NY); 2015 Oct; 7(10):748-9. PubMed ID: 26525307
    [No Abstract]   [Full Text] [Related]  

  • 14. Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF.
    Ding JH; Yuan LY; Huang RB; Chen GA
    Eur J Haematol; 2014 Oct; 93(4):329-39. PubMed ID: 24766194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
    Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
    Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain.
    Iyer D; Vartak SV; Mishra A; Goldsmith G; Kumar S; Srivastava M; Hegde M; Gopalakrishnan V; Glenn M; Velusamy M; Choudhary B; Kalakonda N; Karki SS; Surolia A; Raghavan SC
    FEBS J; 2016 Sep; 283(18):3408-37. PubMed ID: 27444341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
    Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
    Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms.
    Wang H; Yang S; Zhou H; Sun M; Du L; Wei M; Luo M; Huang J; Deng H; Feng Y; Huang J; Zhou Y
    J Hematol Oncol; 2015 Mar; 8():26. PubMed ID: 25886453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel BCL2 inhibitor, Disarib induces apoptosis by disruption of BCL2-BAK interaction.
    Vartak SV; Iyer D; Santhoshkumar TR; Sharma S; Mishra A; Goldsmith G; Srivastava M; Srivastava S; Karki SS; Surolia A; Choudhary B; Raghavan SC
    Biochem Pharmacol; 2017 May; 131():16-28. PubMed ID: 28223017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.